(Q43800989)

26 November 2017

title

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine (English)

1 reference

26 November 2017

F P Bymaster

1

1 reference

26 November 2017

J F Falcone

2

1 reference

26 November 2017

D Bauzon

3

1 reference

26 November 2017

J S Kennedy

4

1 reference

26 November 2017

K Schenck

5

1 reference

26 November 2017

N W DeLapp

6

1 reference

26 November 2017

M L Cohen

7

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

European Journal of Pharmacology

26 November 2017

published in

1 reference

26 November 2017

volume

430

1 reference

26 November 2017

issue

2-3

1 reference

26 November 2017

page(s)

341-349

1 reference

Tardive dyskinesia as a result of long-term prochlorperazine use

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Involvement of 5-HT6 receptors in nigro-striatal function in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

5-ht6 receptors as emerging targets for drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

The pharmacological characterization of 5-HT3 receptors in three isolated preparations derived from guinea-pig tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Does metoclopramide supplement postoperative analgesia using patient-controlled analgesia with morphine in patients undergoing elective cesarean delivery?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

The action of SDZ 205,557 at 5-hydroxytryptamine (5-HT3 and 5-HT4) receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Irritable bowel syndrome: new pharmaceutical approaches to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPgammaS binding assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

5-HT(3) receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

New concepts of irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Insufficient effectiveness of 5-hydroxytryptamine-3 receptor antagonists due to oral morphine administration in patients with cisplatin-induced emesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Association study of serotonin-6 receptor variant (C267T) with schizophrenia and aggressive behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Central distribution and function of 5-HT6 receptor subtype in the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

Ondansetron treatment in patients with Tourette's syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901399-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(01)01399-1

1 reference

26 November 2017

1 reference